Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxyglobin (hemoglobin glutamer-200 (bovine)) is a hemoglobin-based oxygen carrier (HBOC) developed by Biopure Corporation for veterinary use. It consists of ultrapurified, glutaraldehyde-polymerized bovine hemoglobin (13 g/dL) suspended in a modified Lactated Ringer's solution. The polymerization process results in hemoglobin polymers with an average molecular mass of 200 kDa, which remain within the plasma to provide immediate oxygen-carrying capacity. The product is FDA-approved for the treatment of anemia in dogs, regardless of the underlying cause (e.g., hemolysis, blood loss, or ineffective erythropoiesis), by increasing systemic oxygen content and improving clinical signs. It has also been utilized off-label in feline patients for the management of hypotension.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Oxyglobin.